Kotyark Q2 FY27 Profit Rises 147% as Margins Expand

Q2 result highlights

Kotyark Industries reported its unaudited financial results for the quarter ended September 30, 2026. The biofuel manufacturer recorded consolidated profit after tax of ₹6.24 crore in Q2 FY27. This was 147.46% higher than the ₹2.52 crore reported in the corresponding quarter a year earlier. Profit was also 39.85% above the ₹4.46 crore reported in Q1 FY27. Consolidated revenue from operations stood at ₹61.27 crore. Revenue was 5.5% lower year-on-year and 33.4% lower sequentially from Q1 FY27. The result therefore showed a clear divergence between the top line and bottom-line performance. Margin improvement was the main factor behind the higher quarterly profit.

Board approves September-quarter accounts

The board approved the unaudited standalone and consolidated results on October 28, 2026. The results cover the quarter and six months ended September 30, 2026. Kotyark submitted the filing under Regulation 30(6) of the SEBI Listing Regulations. Talati & Talati LLP issued a Limited Review Report on the unaudited financial statements. The filing stated that the review did not identify material misstatements in the accounts. Kotyark had announced earlier that it would report Q2 FY27 results on October 28. The company had also closed its trading window from October 1 ahead of the results. Insiders remain restricted from trading until 48 hours after the declaration.

Revenue declines from a strong June quarter

Consolidated revenue of ₹61.27 crore was below the ₹64.91 crore reported a year earlier. It was also below the ₹91.98 crore recorded in Q1 FY27. The Q1 figure had reflected an 11.5% year-on-year increase from ₹82.46 crore in Q1 FY26. Kotyark's Q2 revenue decline followed that unusually stronger June-quarter base. For the six months ended September 30, sales were ₹153.25 crore. Six-month revenue was ₹153.28 crore, compared with ₹147.40 crore in the previous year. This indicates that first-half revenue remained above the comparable prior-year period. The quarterly result, however, showed that sales momentum was uneven across the first two quarters.

Inventory movement shapes the cost profile

The reported profit improvement coincided with a significant change in the cost structure. Cost of materials consumed was ₹10.17 crore in Q2 FY27. It had been ₹47.41 crore in the year-earlier quarter. The quarterly accounts also reflected a ₹32.83 crore inventory-drawdown adjustment. This indicates that the company drew down finished-goods or trade inventory rather than purchasing equivalent fresh feedstock during the quarter. The lower material-consumption charge supported profitability despite the revenue decline. The supplied financial comparison reported no exceptional items in either year-on-year period. The inventory movement remains important when assessing the sustainability of the quarter's margin performance.

Net margin widens sharply

Kotyark's consolidated net profit margin widened to 10.18% in Q2 FY27. The margin was 3.9% in the corresponding quarter last year. It was 4.9% in Q1 FY27. The increase in margin was therefore visible both year-on-year and sequentially. Earnings per share for the quarter was ₹0.55. The reported EPS was 61.8% higher sequentially. The company stated that EPS calculations reflect its 10:1 bonus share issue made during the June quarter. Prior-period EPS figures have been retrospectively adjusted for the bonus issue.

Consolidated and standalone results differ

Standalone revenue from operations was ₹57.42 crore for the September quarter. Standalone profit after tax was ₹3.71 crore, or ₹370.65 lakh. This represented a 36.6% increase from ₹271.38 lakh in the corresponding quarter last year. Standalone revenue was 8.15% lower than the ₹62.52 crore reported in Q2 FY26. The company attributed improved standalone profitability to lower finance costs and reduced depreciation expenses. Standalone EPS was ₹0.33 for the quarter. The consolidated profit was higher than the standalone figure. Kotyark Bio Specialities Limited contributed ₹2.53 crore of net profit during the quarter, according to the auditor's review.

Key Q2 FY27 financial data

The table shows the different trajectories of revenue and profit in the quarter. Consolidated revenue declined, while consolidated PAT rose substantially. The margin improvement was the central financial development in the result. The standalone business also reported lower revenue but higher profit. Subsidiary performance added to the difference between standalone and consolidated earnings. The financial statements separately identify Kotyark Bio Specialities as a meaningful contributor to consolidated profit. The other two subsidiaries had nil revenue and near-zero results in the period cited. These details provide context for the consolidated earnings outcome.

Order book and operating context

Kotyark had reported an order book of ₹173.45 crore from oil marketing companies at the time of its Q1 FY27 update. That disclosure provides operating context for the company's revenue position. The September-quarter results do not provide a new order-book figure. The company reported Q1 FY27 consolidated revenue of ₹91.98 crore and profit of ₹4.46 crore. Q1 profit was 9% above the corresponding prior-year period. In Q2, consolidated profit accelerated even as revenue declined. The latest result underscores the role of costs, inventory accounting and subsidiary contributions in quarterly profitability. Investors will have to assess subsequent disclosures for evidence of revenue normalisation and repeatability of margins.

What the Q2 numbers mean

Kotyark's Q2 FY27 result was marked by strong profit growth rather than revenue growth. Consolidated PAT rose to ₹6.24 crore from ₹2.52 crore a year earlier. Net margin expanded to 10.18% from 3.9%. At the same time, revenue declined to ₹61.27 crore from ₹64.91 crore. The inventory drawdown and lower material-consumption charge were material to the quarter's cost profile. Standalone profitability also improved, supported by lower finance costs and depreciation. The 10:1 bonus issue has been incorporated into EPS comparisons. The next financial disclosures will provide further clarity on revenue trends, inventory movements and the contribution from subsidiaries.